Roivant Sciences Ltd. (ROIV)

NasdaqGS Currently down 0.49 (-1.72%) in today's trading session

Track congressional stock trades in Roivant Sciences Ltd. (ROIV). Analyze trading activity from Nancy Pelosi and other members of Congress with real-time financial disclosure data, interactive price charts, and detailed transaction records.

Roivant Sciences Ltd. is currently trading at $28.06, positioned at 89% of its 52-week range ($8.73 – $30.33). View which politicians have recently bought or sold ROIV and how their trades align with market movements.

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio in real-time with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$28.06
24h Change
-0.49 (-1.72%)
52 Week Range
$8.73$30.33
View on NASDAQ

Roivant Sciences Ltd. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ROIV

Select to highlight on chart
3 transactions
Compliance: 75%
Lisa McClain31 Oct 202521 Nov 2025SaleStock$1,001 - $15,000N/A (Sale Transaction)
Lisa McClain30 Oct 202521 Nov 2025SaleStock$1,001 - $15,000N/A (Sale Transaction)
Lisa McClain30 Oct 202521 Nov 2025PurchaseStock$1,001 - $15,000+49.57%

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$20.08B

Volume

5.46M

Beta

1.21

P/E Ratio

-23.98

Fundamentals

EPS

$-1.17

Div. Yield

Open

$28.87

Day Range

$27.93 — $29.23

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
GB
CEO
Matthew Gline
IPO Date
2020-12-08

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypo...

Earnings

Next Report

Q1 2026

4 Jun

EPS Est.

$-0.26

Rev. Est.

Days Until

82

Recent Quarters

Q4 20256 Feb
EPS$-0.24
Beat 19.9%
Q3 202510 Nov
EPS$-0.28
Beat 12.4%
Q2 202511 Aug
EPS$-0.18
Beat 27.9%
Q1 202529 May
EPS$-0.22
Beat 16.5%
Q4 202410 Feb
EPS$-0.13
Beat 45.8%
Q3 202412 Nov
EPS$-0.29
Miss 17.4%
Q2 20248 Aug
EPS$-0.18
Beat 26.0%
Q1 202430 May
EPS$-0.23
Beat 13.0%
Q4 202313 Feb
EPS$-0.21
Beat 22.2%
Q3 202313 Nov
EPS$-0.26
Beat 7.1%
Q2 202314 Aug
EPS$-0.38
Miss 46.1%
Q1 202328 Jun
EPS$-0.20
Beat 51.2%
Q4 202213 Feb
EPS$-0.49
Miss 36.1%
Q3 202214 Nov
EPS$-0.42
Miss 2.4%
Q2 202215 Aug
EPS$-0.48
Miss 60.0%
Q1 202228 Jun
EPS$-0.39
Miss 56.0%
Q4 202114 Feb
EPS$-0.41
Miss 78.3%
Q3 202115 Nov
EPS$-0.26
Beat 42.2%
Q2 202121 Sept
EPS
Q2 202110 Aug
EPS

3 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

PLTR

Palantir Technologies Inc.

20
$150.95-2.55 (-1.66%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

TSM

Taiwan Semiconductor Manufacturing Company Limited

20
$338.31+1.60 (+0.48%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

IVV

iShares Core S&P 500 ETF

17
$665.20-3.75 (-0.56%)
Financial Services
Held by same politician
1 politician
View Stock
Pelosi TrackerJoin our Discord © 2026 - All rights reserved. This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.